Search hospitals > California > Riverside

Kaiser Permanente-Riverside

Claim this profile
Riverside, California 92505
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
143 reported clinical trials
8 medical researchers
Photo of Kaiser Permanente-Riverside in RiversidePhoto of Kaiser Permanente-Riverside in RiversidePhoto of Kaiser Permanente-Riverside in Riverside

Summary

Kaiser Permanente-Riverside is a medical facility located in Riverside, California. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Kaiser Permanente-Riverside is involved with conducting 143 clinical trials across 344 conditions. There are 8 research doctors associated with this hospital, such as Helen H. Moon, Gary L. Buchschacher, Eric C. McGary, and Ashraf R. Aziz.

Area of expertise

1Cancer
Global Leader
Kaiser Permanente-Riverside has run 53 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Lung Cancer
Global Leader
Kaiser Permanente-Riverside has run 28 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage I

Top PIs

Clinical Trials running at Kaiser Permanente-Riverside

Non-Small Cell Lung Cancer
Lung Cancer
Breast Cancer
Prostate Cancer
Diffuse Large B-Cell Lymphoma
Cancer
Lymphoma
Colorectal Cancer
Small Intestinal Adenocarcinoma
Anal Squamous Cell Carcinoma
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This study is evaluating whether the addition of a drug to chemotherapy may help treat non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Ramucirumab + Pembrolizumab vs Chemotherapy

for Non-Small Cell Lung Cancer

This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.
Recruiting2 awards Phase 310 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This study is evaluating whether a drug called crizotinib may help treat patients with non-small cell lung cancer.
Recruiting2 awards Phase 328 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Kaiser Permanente-Riverside?
Kaiser Permanente-Riverside is a medical facility located in Riverside, California. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Kaiser Permanente-Riverside is involved with conducting 143 clinical trials across 344 conditions. There are 8 research doctors associated with this hospital, such as Helen H. Moon, Gary L. Buchschacher, Eric C. McGary, and Ashraf R. Aziz.